Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Merck & Co has axed two hepatitis drugs in its pipeline ... a deep undercutting of Epclusa’s list price of $74,760 for a 12 week course - and analysts think this move could spark a price ...

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

With list prices of $8.94 per day for the monotherapy ... the other leading market for the drugs. Merck and Pfizer began a collaboration in 2013, covering the whole world except Japan, for co ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...